welcome to oneFAPvoice
- a positively charged Familial Adenomatous Polyposis community.- join today!
- login
Cancer Prevention Pharmaceuticals (CPP) and Mallinckrodt Announce Results from Pivotal Phase 3 Trial of CPP-1X/Sulindac in Patients With Familial Adenomatous Polyposis
Cancer Prevention Pharmaceuticals, Inc., a private biotech company developing novel therapeutics to prevent cancer and other diseases, and its partner Mallinckrodt Plc, a leading global specialty pharmaceutical company, today announced that CPP’s pivotal phase 3 clinical trial, CPP FAP-310, of the investigational drug CPP-1X/sulindac in patients with familial adenomatous polyposis (FAP), did not meet its primary endpoint. Specifically, the reduction of time to the first occurrence of an FAP-related event for the combination of CPP-1X (eflornithine) and sulindac (a nonsteroidal anti-inflammatory drug) did not reach statistical significance compared to the two control arms. CPP FAP-310 included only active comparator arms and was the largest and longest study ever conducted in patients with FAP.
“While we are disappointed that the CPP FAP-310 clinical trial did not achieve its primary endpoint, we are encouraged by the data that relate to important outcome measures,” said CPP CEO Jeff Jacob.
expertly curated content related to this topic
-
Mayo Clinic Researcher Finds Potential Target to Control Rare Genetic Disease That Strikes in Teen YearsA new study from researchers at Mayo Cli...
-
Dennis J. Ahnen, MD (Deceased)Research Interests: Dr. Ahnen’s res...
-
Chemoprevention of Familial Adenomatous PolyposisFamilial adenomatous polyposis (FAP) has...
-
The Effects of Sulindac on the Pathology of Colorectal Remnant Polyps of Familial Adenomatous Polyposis (FAP) Patien...OBJECTIVE : To evaluate the long-term ef...
-
Clinical Management of Adenomatous Polyposis in Patients with Hereditary Non-Polyposis Colorectal Cancer and Familia...OBJECTIVE : To investigate the validity ...
-
Celecoxib, DFMO combination improved adenoma burden in patients with familial adenomatous polyposisIn a randomized clinical chemoprevention...
-
Evelien DekkerDr. Evelien Dekker is a board-qualified ...